Stage 4S Neuroblastoma: What Are the Outcomes? A Systematic Review of Published Studies

Systematic review of 1,105 stage 4S/MS neuroblastoma patients reveals 84% overall survival, but outcomes vary dramatically by molecular markers and treatment approach. MYCN amplification carries 56% mortality while conservative management or primary tumor resection alone show best outcomes (6.5-8.5% mortality).